The role of SARS-CoV-2 testing in COVID-19

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the novel coronavirus that causes coronavirus disease 2019 (COVID-19) and has escalated, becoming a pandemic in early 2020. Multiple testing modalities have been developed to detect this virus including RT-PCR, antigen, and serology tes...

Full description

Bibliographic Details
Main Author: Cole, Manisha
Other Authors: Kataria, Yachana
Language:en_US
Published: 2021
Subjects:
Online Access:https://hdl.handle.net/2144/43341
id ndltd-bu.edu-oai-open.bu.edu-2144-43341
record_format oai_dc
spelling ndltd-bu.edu-oai-open.bu.edu-2144-433412021-11-17T05:01:37Z The role of SARS-CoV-2 testing in COVID-19 Cole, Manisha Kataria, Yachana Epidemiology Antibodies Antigen testing COVID-19 SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the novel coronavirus that causes coronavirus disease 2019 (COVID-19) and has escalated, becoming a pandemic in early 2020. Multiple testing modalities have been developed to detect this virus including RT-PCR, antigen, and serology testing. RT-PCR testing is the clinical gold standard and is used for diagnostic purposes of current infections. Antigen testing is rapid and requires significantly less equipment, but lacks the sensitivity of RT-PCR testing. Serology assays detect antibodies raised against SARS-CoV-2, so only detect prior exposure. It is important to note that use of antibody tests may also detect prior asymptomatic infections. For these reasons, it is imperative that all testing modalities be continuously developed and improved to better our understanding of disease transmission, helping to inform and change infection control policies and protecting both employees in the workplace and patients. We aim to quantify the seroprevalence of anti-SARS-CoV-2 IgG in the healthcare workers at Boston Medical Center, including those with asymptomatic infections. Our results show an overall seroprevalence of 5.5% with an asymptomatic seroprevalence of 1.8%. High risk groups include those who are obese, smokers, and Hispanic/LatinX. Experiencing some symptoms was associated with a higher risk of seropositivity, as was lack of social distancing amongst coworkers. In a separate study, we aim to assess the direct antigen rapid tests (DART) created by E25Bio in patients seeking care at Boston Medical Center. This study has been significantly limited by number of participants, as recruitment has been paused during both COVID-19 surges in Boston, MA. The current data shows poor positive agreement between DART and RT-PCR, but acceptable negative agreement. Each testing modality works to fill in the gaps of knowledge that still persist around SARS-CoV-2. Each of these testing types provides a unique piece of information and when used together, will help to inform strategies to overcome the SARS-CoV-2 pandemic. 2021-11-15T18:20:48Z 2021-11-15T18:20:48Z 2021 2021-11-10T23:06:41Z Thesis/Dissertation https://hdl.handle.net/2144/43341 en_US
collection NDLTD
language en_US
sources NDLTD
topic Epidemiology
Antibodies
Antigen testing
COVID-19
SARS-CoV-2
spellingShingle Epidemiology
Antibodies
Antigen testing
COVID-19
SARS-CoV-2
Cole, Manisha
The role of SARS-CoV-2 testing in COVID-19
description Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the novel coronavirus that causes coronavirus disease 2019 (COVID-19) and has escalated, becoming a pandemic in early 2020. Multiple testing modalities have been developed to detect this virus including RT-PCR, antigen, and serology testing. RT-PCR testing is the clinical gold standard and is used for diagnostic purposes of current infections. Antigen testing is rapid and requires significantly less equipment, but lacks the sensitivity of RT-PCR testing. Serology assays detect antibodies raised against SARS-CoV-2, so only detect prior exposure. It is important to note that use of antibody tests may also detect prior asymptomatic infections. For these reasons, it is imperative that all testing modalities be continuously developed and improved to better our understanding of disease transmission, helping to inform and change infection control policies and protecting both employees in the workplace and patients. We aim to quantify the seroprevalence of anti-SARS-CoV-2 IgG in the healthcare workers at Boston Medical Center, including those with asymptomatic infections. Our results show an overall seroprevalence of 5.5% with an asymptomatic seroprevalence of 1.8%. High risk groups include those who are obese, smokers, and Hispanic/LatinX. Experiencing some symptoms was associated with a higher risk of seropositivity, as was lack of social distancing amongst coworkers. In a separate study, we aim to assess the direct antigen rapid tests (DART) created by E25Bio in patients seeking care at Boston Medical Center. This study has been significantly limited by number of participants, as recruitment has been paused during both COVID-19 surges in Boston, MA. The current data shows poor positive agreement between DART and RT-PCR, but acceptable negative agreement. Each testing modality works to fill in the gaps of knowledge that still persist around SARS-CoV-2. Each of these testing types provides a unique piece of information and when used together, will help to inform strategies to overcome the SARS-CoV-2 pandemic.
author2 Kataria, Yachana
author_facet Kataria, Yachana
Cole, Manisha
author Cole, Manisha
author_sort Cole, Manisha
title The role of SARS-CoV-2 testing in COVID-19
title_short The role of SARS-CoV-2 testing in COVID-19
title_full The role of SARS-CoV-2 testing in COVID-19
title_fullStr The role of SARS-CoV-2 testing in COVID-19
title_full_unstemmed The role of SARS-CoV-2 testing in COVID-19
title_sort role of sars-cov-2 testing in covid-19
publishDate 2021
url https://hdl.handle.net/2144/43341
work_keys_str_mv AT colemanisha theroleofsarscov2testingincovid19
AT colemanisha roleofsarscov2testingincovid19
_version_ 1719494027158487040